Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Collyar: What's In It for Patients?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Aug

Today In Oncology

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Collyar: What's In It for Patients?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care

AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer

First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer

NIH-Funded International Research Yields Patient-Derived Tumor Compendium

Stanford Appoints New Leader to Expand Impact in Early Drug Development